Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J9206
20 MG
Medicare payment limit per unit (Q4 2026): $1.569
| Setting | Max units / day | Adjudication (MAI) | CMS rationale |
|---|---|---|---|
| Practitioner services (professional claims) | 42 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| Facility outpatient hospital services | 42 | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. | Prescribing Information |
| DME supplier services | 0Not reportable in this setting | 3 Date of Service Edit: ClinicalDate-of-service edit (clinical benchmarks): more units for the same patient and date are possible but medically highly unlikely; documentation of medical necessity may be considered. |
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$1.569per 20 MG
Effective Oct 1, 2026 – Dec 31, 2026 · AMP-based payment limit (per CMS note) · based on Q2 2026 ASP data · coinsurance 20.000%
CMS note: “AMP-based payment limit”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $1.569 | 20 MG | 20% | −15.2% | AMP-based payment limit |
| Q3 2026 | Jul 1, 2026 – Sep 30, 2026 | $1.851 | 20 MG | 20% | +20.8% |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 45963-0614-51 | Irinotecan HClActavis Pharma, Inc. | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 45963-0614-55 | Irinotecan HClActavis Pharma, Inc. | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 60505-6128-00 | Irinotecan HClApotex Corp | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 60505-6128-01 | Irinotecan HClApotex Corp | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 60505-6272-01 | Irinotecan HClApotex Corp | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2024 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 68001-0480-22 | Irinotecan HClBluePoint Laboratories | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2024 – Q4 2026 | ListedIrinotecan hydrochloide |
| 68001-0480-35 | Irinotecan HClBluePoint Laboratories | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2024 – Q4 2026 | ListedIrinotecan hydrochloide |
| 55150-0352-01 | Irinotecan HClEugia US LLC | 2 × 1 | 2 | 2 | $3.14 | ASP | Q3 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 55150-0353-01 | Irinotecan HClEugia US LLC | 5 × 1 | 5 | 5 | $7.85 | ASP | Q3 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 55150-0354-01 | Irinotecan HClEugia US LLC | 15 × 1 | 15 | 15 | $23.54 | ASP | Q3 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 63323-0193-52 | Irinotecan HClFreseniUS Kabi USA, LLC | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 63323-0193-55 | Irinotecan HClFreseniUS Kabi USA, LLC | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 00143-9701-01 | Irinotecan HClHikma Pharmaceuticals USA Inc. | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 00143-9702-01 | Irinotecan HClHikma Pharmaceuticals USA Inc. | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 50742-0401-02 | Irinotecan HClIngenus Pharmaceuticals LLC | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | Excluded listingIrinotecan Hydrochloride |
| 50742-0402-05 | Irinotecan HClIngenus Pharmaceuticals LLC | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | Excluded listingIrinotecan Hydrochloride |
| 16714-0027-01 | Irinotecan HClNorthstar RxLLC | 2 × 1 | 2 | 2 | $3.14 | ASP | Q2 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 16714-0131-01 | Irinotecan HClNorthstar RxLLC | 5 × 1 | 5 | 5 | $7.85 | ASP | Q2 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 00009-0082-02 | CamptosarPfizer Inc | 15 × 1 | 15 | 15 | $23.54 | ASP | Q1 2025 – Q4 2026 | ListedCamptosar |
| 00009-0112-05 | CamptosarPfizer Inc | 5 × 1 | 5 | 5 | $7.85 | ASP | Q3 2025 – Q4 2026 | ListedCamptosar |
| 00009-7529-03 | CamptosarPfizer Inc | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | Excluded listingCamptosar |
| 00009-7529-04 | CamptosarPfizer Inc | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | Excluded listingCamptosar |
| 00009-7529-05 | CamptosarPfizer Inc | 15 × 1 | 15 | 15 | $23.54 | ASP | Q1 2021 – Q4 2026 | ListedCamptosar |
| 00009-7529-10 | CamptosarPfizer Inc | 2 × 1 | 2 | 2 | $3.14 | ASP | Q3 2025 – Q4 2026 | ListedCamptosar |
| 61703-0349-09 | Irinotecan HClPfizer Inc | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 61703-0349-16 | Irinotecan HClPfizer Inc | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 61703-0349-36 | Irinotecan HClPfizer Inc | 25 × 1 | 25 | 25 | $39.23 | ASP | Q1 2021 – Q4 2026 | ListedIrinotecan Hydrochloride |
| 25021-0230-02 | Irinotecan HClSagent Pharmaceuticals | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2021 – Q4 2026 | Excluded listingIrinotecan Hydrochloride |
| 25021-0230-05 | Irinotecan HClSagent Pharmaceuticals | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2021 – Q4 2026 | Excluded listingIrinotecan Hydrochloride |
| 70700-0169-22 | Irinotecan HClXiromed, LLC | 2 × 1 | 2 | 2 | $3.14 | ASP | Q1 2024 – Q4 2026 | ListedIrinotecan hydrochloide |
| 70700-0170-22 | Irinotecan HClXiromed, LLC | 5 × 1 | 5 | 5 | $7.85 | ASP | Q1 2024 – Q4 2026 | ListedIrinotecan Hydrochloride |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|
| 45963-0614-81 | Irinotecan HClACTAVIS PHARMA, INC. | 2 × 1 | 2 | 2 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file |
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q1 2023 | In earliest ingested file | N — No maintenance | Added date Jan 1, 1998 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.
| CMS Policy |
An MUE is the most units CMS expects for this code for one patient on one date of service by the same provider in most correctly reported claims. CMS MUE program
| AMP-based payment limit |
| Q2 2026 | Apr 1, 2026 – Jun 30, 2026 | $1.532 | 20 MG | 20% | −14.6% | AMP-based payment limit |
|---|
| Q1 2026 | Jan 1, 2026 – Mar 31, 2026 | $1.794 | 20 MG | 20% | +2.5% | AMP-based payment limit |
|---|
| Q4 2025 | Oct 1, 2025 – Dec 31, 2025 | $1.751 | 20 MG | 20% | +25.3% | AMP-based payment limit |
|---|
| Q3 2025 | Jul 1, 2025 – Sep 30, 2025 | $1.397 | 20 MG | 20% | −14.8% | AMP-based payment limit |
|---|
| Q2 2025 | Apr 1, 2025 – Jun 30, 2025 | $1.640 | 20 MG | 20% | −16.9% | — |
|---|
| Q1 2025 | Jan 1, 2025 – Mar 31, 2025 | $1.974 | 20 MG | 20% | −21.0% | AMP-based payment limit |
|---|
| Q4 2024 | Oct 1, 2024 – Dec 31, 2024 | $2.498 | 20 MG | 20% | −7.9% | — |
|---|
| Q3 2024 | Jul 1, 2024 – Sep 30, 2024 | $2.712 | 20 MG | 20% | −22.7% | — |
|---|
| Q2 2024 | Apr 1, 2024 – Jun 30, 2024 | $3.508 | 20 MG | 20% | +80.4% | — |
|---|
| Q1 2024 | Jan 1, 2024 – Mar 31, 2024 | $1.945 | 20 MG | 20% | −5.8% | — |
|---|
| Q4 2023 | Oct 1, 2023 – Dec 31, 2023 | $2.064 | 20 MG | 20% | −31.3% | — |
|---|
| Q3 2023 | Jul 1, 2023 – Sep 30, 2023 | $3.003 | 20 MG | 20% | +39.0% | — |
|---|
| Q2 2023 | Apr 1, 2023 – Jun 30, 2023 | $2.160 | 20 MG | 20% | −11.0% | — |
|---|
| Q1 2023 | Jan 1, 2023 – Mar 31, 2023 | $2.428 | 20 MG | — | −6.8% | — |
|---|
| Q4 2022 | Oct 1, 2022 – Dec 31, 2022 | $2.604 | 20 MG | — | +9.7% | — |
|---|
| Q3 2022 | Jul 1, 2022 – Sep 30, 2022 | $2.373 | 20 MG | — | +3.3% | — |
|---|
| Q2 2022 | Apr 1, 2022 – Jun 30, 2022 | $2.297 | 20 MG | — | −6.2% | — |
|---|
| Q1 2022 | Jan 1, 2022 – Mar 31, 2022 | $2.449 | 20 MG | — | +4.3% | — |
|---|
| Q4 2021 | Oct 1, 2021 – Dec 31, 2021 | $2.348 | 20 MG | — | −5.8% | — |
|---|
| Q3 2021 | Jul 1, 2021 – Sep 30, 2021 | $2.493 | 20 MG | — | +2.7% | — |
|---|
| Q2 2021 | Apr 1, 2021 – Jun 30, 2021 | $2.427 | 20 MG | — | −0.9% | — |
|---|
| Q1 2021 | Jan 1, 2021 – Mar 31, 2021 | $2.449 | 20 MG | — | — | — |
|---|
| 45963-0614-85 | Irinotecan HClACTAVIS PHARMA, INC. | 5 × 1 | 5 | 5 | ASP | Q1 2021 – Q4 2024Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|
| 68001-0284-25 | Irinotecan HCLAMERICAN HEALTH PACKAGING | 5 × 1 | 5 | 5 | ASP | Q1 2021 – Q4 2023Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|
| 68001-0284-34 | Irinotecan HCLAMERICAN HEALTH PACKAGING | 2 × 1 | 2 | 2 | ASP | Q1 2021 – Q4 2021Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|
| 72485-0211-02 | Irinotecan HClArmas Pharmaceuticals Inc. | 2 × 1 | 2 | 2 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride 40 mg/2 mL |
|---|
| 72485-0212-05 | Irinotecan HClArmas Pharmaceuticals Inc. | 5 × 1 | 5 | 5 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride 100 mg/5 mL |
|---|
| 72485-0213-15 | Irinotecan HClArmas Pharmaceuticals Inc. | 15 × 1 | 15 | 15 | ASP | Q1 2021 – Q4 2025Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|
| 00143-9583-01 | Irinotecan HClHikma Pharmaceuticals USA Inc. | 5 × 1 | 5 | 5 | ASP | Q1 2021 – Q1 2025Not in Q4 2026 file | ListedIrinotecan Hydrochloride |
|---|
| 16714-0726-01 | Irinotecan HCLNORTHSTAR RX LLC | 5 × 1 | 5 | 5 | ASP | Q1 2021 – Q3 2022Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|
| 00703-4432-11 | Irinotecan HCLSICOR PHARMACEUTICALS, INC. | 2 × 1 | 2 | 2 | ASP | Q1 2021 – Q2 2022Not in Q4 2026 file | Excluded listingIrinotecan Hydrochloride |
|---|